<DOC>
	<DOC>NCT00357110</DOC>
	<brief_summary>Purpose is to compare the frequency of events (presence of Disseminated Tumour Cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or anastrozole alone in patients with early breast cancer.</brief_summary>
	<brief_title>Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal women with hormone receptorpositive early breast cancer and a positive Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior to randomisation Inflammatory and/or metastatic breast cancer. Current or previous malignancy within previous 5 years (other than Breast cancer or adequately treated nonmelanoma skin cancer or insitu cervical cancer). History of bleeding diathesis.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Breast neoplasms</keyword>
	<keyword>breast cancer</keyword>
	<keyword>early breast cancer</keyword>
	<keyword>oncology</keyword>
	<keyword>cancer</keyword>
	<keyword>breast cancer micrometastasis</keyword>
	<keyword>fulvestrant</keyword>
</DOC>